New drug to treat chronic kidney disease gets approval
- February 16, 2024
- Posted by: OptimizeIAS Team
- Category: DPN Topics
No Comments
New drug to treat chronic kidney disease gets approval
Subject: Science and tech
Section: Health
Context:
- The Central Drugs Standard Control Organisation (CDSCO) has approved Jardiance (empagliflozin) 10mg tablets for end-stage kidney and cardiovascular diseases.
More on news:
- It will reduce the risk of sustained decline in patients with end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
- Jardiance is not recommended for the treatment of CKD in patients with polycystic kidney disease.
- According to CDSCO, this indication approval allows nephrologists and cardiologists to use Jardiance 10mg tablets for the treatment of CKD in eligible patients.
About Empagliflozin:
- It is used to treat type 2 diabetes.
- It works in the kidneys to prevent absorption of glucose (blood sugar).
- This helps lower the blood sugar level.
- Empagliflozin does not help patients who have insulin-dependent or type 1 diabetes.